Volume 14, Issue 4 (2023)                   JMBS 2023, 14(4): 1-10 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sefidi-Heris Y, Saadat I. Metformin and p-coumaric acid alter the expression of some EMT genes in gastric cancer cell line AGS. JMBS 2023; 14 (4) :1-10
URL: http://biot.modares.ac.ir/article-22-72337-en.html
1- Department of Biology, School of Science, Shiraz University, Shiraz, Iran
2- Department of Biology, School of Science, Shiraz University, Department of Biology, School of Science, Shiraz University, Shiraz 71467-13565, Iran , isaadat@shirazu.ac.ir
Abstract:   (894 Views)
Gastric cancer is one of the most common cancers in the world. Its treatments are costly and can cause severe side effects. As a result, treatments with natural compounds, well-established therapeutics, or combinations of both groups may be effective alternatives. p-Coumaric acid (pCA) and metformin (Met) are among such anticancer treatments. Epithelial-mesenchymal transition (EMT) is a multi-purpose process that plays a critical role in gastric cancer. This process involves a complex network of biological markers participating in gastric cancer initiation and metastasis. Subsequently, the agents downregulating the expression of EMT markers may be potential anti-gastric cancer therapeutics. Because the effects of pCA, Met, and their combination on the expression of EMT markers ZEB1, Snail2, Vimentin, and VEGFA have not been inspected, the present study aimed at assessing these effects. MTT assay determined the cytotoxicity of pCA and Met on the AGS cells for 48 hours. Real-time PCR was used to evaluate the changes in the expression levels of these EMT genes after 48 hours. A combination of pCA and Met downregulated the expression of ZEB1 and Vimentin genes at low, non-cytotoxic concentrations. Therefore, they may be potential candidates for further investigations in fighting against gastric cancer.
 
Full-Text [PDF 206 kb]   (514 Downloads)    
Article Type: Original Research | Subject: Pharmaceutical Biotechnology
Received: 2023/11/9 | Accepted: 2023/12/4 | Published: 2024/06/16

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.